Exploiting research conducted at Kyoto Prefecture University of Medicine, Aurion Biotech is focusing on therapies that can restore vision.

Aurion Biotech, a US-based ophthalmology-focused regenerative therapies developer based on work at Kyoto Prefecture University of Medicine, obtained $120m in funding yesterday led by Deerfield Management.

Eye care products developer Alcon took part in the round, as did Petrichor Healthcare Capital Management, Flying L Partners, KKR-backed Falcon Vision and Visionary Ventures.

Aurion Biotech’s initial programme is a cell therapy aimed at corneal oedema secondary to endothelial dysfunction, a condition that leads to vision loss and can currently only be treated…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email Linked in